Pasithea Therapeutics Files 8-K
Ticker: KTTAW · Form: 8-K · Filed: Nov 25, 2025 · CIK: 1841330
Sentiment: neutral
Topics: disclosure, corporate-events
TL;DR
Pasithea Therapeutics filed an 8-K on Nov 25th, reporting events from Nov 20th. Check for details on Reg FD, other events, and financials.
AI Summary
Pasithea Therapeutics Corp. filed an 8-K on November 25, 2025, reporting events that occurred on November 20, 2025. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in Delaware and its principal executive offices are located in Miami Beach, Florida.
Why It Matters
This 8-K filing indicates that Pasithea Therapeutics Corp. is disclosing important corporate events and potentially financial information to the public, which could impact investor understanding of the company's status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K, primarily providing disclosures and administrative information without immediate, significant financial or operational news.
Key Players & Entities
- Pasithea Therapeutics Corp. (company) — Registrant
- November 20, 2025 (date) — Earliest event reported
- November 25, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Miami Beach, Florida (location) — Principal executive offices
FAQ
What specific events are being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in this excerpt.
What are the 'Other Events' being reported by Pasithea Therapeutics Corp.?
The filing lists 'Other Events' as a category, but the specific nature of these events is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on November 20, 2025.
Where are Pasithea Therapeutics Corp.'s principal executive offices located?
Pasithea Therapeutics Corp.'s principal executive offices are located at 1111 Lincoln Road, Suite 500, Miami Beach, Florida, 33139.
What is the SIC code for Pasithea Therapeutics Corp.?
The Standard Industrial Classification (SIC) code for Pasithea Therapeutics Corp. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,893 words · 8 min read · ~6 pages · Grade level 13.3 · Accepted 2025-11-25 16:15:29
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share KTTA The Nasdaq Capital M
- $1 million — n ALS Clinical Trial Award grant worth ~$1 million to study PAS-004 in ALS patients. The a
Filing Documents
- ea0266606-8k_pasithea.htm (8-K) — 59KB
- ea026660601ex99-1_pasithea.htm (EX-99.1) — 21KB
- ea026660601ex99-2_pasithea.htm (EX-99.2) — 14KB
- ea026660601ex99-3_pasithea.htm (EX-99.3) — 22KB
- ea026660601ex99-4_pasithea.htm (EX-99.4) — 12KB
- image_001.jpg (GRAPHIC) — 10KB
- image_002.jpg (GRAPHIC) — 10KB
- image_003.jpg (GRAPHIC) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 20KB
- ex99-2_001.jpg (GRAPHIC) — 20KB
- ex99-2_002.jpg (GRAPHIC) — 10KB
- ex99-2_003.jpg (GRAPHIC) — 10KB
- ex99-3_001.jpg (GRAPHIC) — 6KB
- ex99-3_002.jpg (GRAPHIC) — 10KB
- ex99-4_001.jpg (GRAPHIC) — 6KB
- 0001213900-25-114763.txt ( ) — 555KB
- ktta-20251120.xsd (EX-101.SCH) — 4KB
- ktta-20251120_def.xml (EX-101.DEF) — 26KB
- ktta-20251120_lab.xml (EX-101.LAB) — 36KB
- ktta-20251120_pre.xml (EX-101.PRE) — 25KB
- ea0266606-8k_pasithea_htm.xml (XML) — 6KB
01 Regulation FD
Item 7.01 Regulation FD On November 20, 2025, Pasithea Therapeutics Corp. (the "Company") issued the November 20 Press Release (as defined below). A copy of the November 20 Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein. On November 21, 2025, the Company issued the November 21 Press Release (as defined below). A copy of the November 21 Press Release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is hereby incorporated by reference herein. On November 24, 2025, the Company issued the November 24 Press Release (as defined below). A copy of the November 24 Press Release is furnished as Exhibit 99.3 to this Current Report on Form 8-K and is hereby incorporated by reference herein. On November 25, 2025, the Company issued the November 25 Press Release (as defined below). A copy of the November 25 Press Release is furnished as Exhibit 99.4 to this Current Report on Form 8-K and is hereby incorporated by reference herein. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, Exhibit 99.2, Exhibit 99.3, and Exhibit 99.4, is being furnished to the Securities and Exchange Commission (the "SEC"), and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
01 Other Events
Item 8.01 Other Events. On November 20, 2025, the Company issued a press release (the "November 20 Press Release") relating to positive interim Phase 1 data from its ongoing first-in-human clinical trial of PAS-004 in patients with advanced solid tumors driven by MAPK pathway alterations, including documented RAS, NF1 or RAF mutations, and in patients who have failed prior BRAF/MEK inhibition. The Company released the below interim Phase 1 results for PAS-004 in the Press Release: Initial Signals of Clinical Activity Among 21 efficacy evaluable patients (as per RECIST1.1): Partial Response: A BRAF V600E melanoma patient in Cohort 4A (15mg capsule) achieved an unconfirmed partial response with a –31.9% tumor reduction and remains on trial for >11 months; prior best response when treated with a MEK + BRAF combination therapy was stable disease Disease Control Rate (DCR): 71.4% (5 of 7) of patients identified with BRAF-mutated tumors achieved stable disease or partial response 42.8% (9 of 21) of patients achieved stable disease or partial response Durable Stable Disease: A second BRAF V600E melanoma patient previously treated with MEK + BRAF combination therapy in Cohort 6 (30mg capsule) remains on trial for >6 months with a stable disease and tumor shrinkage of -1.6% Safety and Tolerability Among 27 dosed patients through the Dose Limiting Toxicity (DLT) period (Day 28) through the cutoff date of November 10, 2025: PAS-004, dosed once daily (QD), has been well-tolerated across all dose levels 1 No dose-limiting toxicities (DLTs) , and no discontinuations have been reported. All treatment-related adverse events (TRAEs) at least possible related to PAS-004 were Grade 1 or 2 , with limited rash (7.4%), nausea (18.5%), vomiting (14.8%), diarrhea (7.4%), and no ocular retinal abnormalities or cardiovascular toxicities observed. Pharmacokinetics (PK) PAS-004 has demonstrated through Cohort 6: Linear PK and dose-proportionality PK curve
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains statements that constitute "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company's ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company's ongoing Phase 1/1b clinical trial of PAS-004 in adult patients with NF1-associated plexiform neurofibromas, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company's current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company's plans, assumptions, expectations, beliefs and objectives, the success of the Company's current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this Current Report. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company's most recent A
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated November 20, 2025 . 99.2 Press Release dated November 21, 2025 . 99.3 Press Release dated November 24, 2025 . 99.4 Press Release dated November 25, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 4 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PASITHEA THERAPEUTICS CORP. Date: November 25, 2025 By: /s/ Tiago Reis Marques Name: Tiago Reis Marques Title: Chief Executive Officer 5